Skip to main content

Table 3 Representative ongoing clinical trials using CTLA-4/PD-1/PD-L1 inhibitors and RT for malignant tumors

From: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

ClinicalTrials.gov identifier

Phase

Conditions

Drug classification

Interventions

Sponsors

NCT01996202

Phase 1

Melanoma

CTLA-4 inhibitors

Ipilimumab with radiation therapy

Duke University

NCT02642809

Phase 1

EC

PD-1 inhibitors

Pembrolizumab with brachytherapy (16 Gy in 2 fractions)

Washington University School of Medicine

NCT02837263

Phase 1

Colorectal cancer

PD-1 inhibitors

Pembrolizumab with SBRT (40–60 Gy in 5 fractions)

University of Wisconsin, Madison

NCT02587455

Phase 1

Thoracic tumors

PD-1 inhibitors

Arm I: pembrolizumab with low-dose radiation therapy

Arm II: pembrolizumab with high-dose radiation therapy

Royal Marsden NHS Foundation Trust

NCT03151447

Phase 1

TNBC

PD-L1 inhibitors

JS001 with SBRT

Fudan University

NCT02868632

Phase 1

Pancreatic cancer

PD-L1 and CTLA-4 inhibitors

Durvalumab or/and tremelimumab with SBRT (30 Gy in 5 fractions)

New York University School of Medicine

NCT03275597

Phase 1

NSCLC

PD-L1 and CTLA-4 inhibitors

Durvalumab and tremelimumab with SBRT (30–50 Gy in 5 fractions)

University of Wisconsin, Madison

NCT02239900

Phase 1/2

Liver cancer, lung cancer

CTLA-4 inhibitors

Ipilimumab with SBRT

M.D. Anderson Cancer Center

NCT03050554

Phase 1/2

NSCLC

PD-L1 inhibitors

Avelumab with SBRT (48 Gy in 4 fractions or 50 Gy in 5 fractions)

Andrew Sharabi

NCT02696993

Phase 1/2

Brain metastases (NSCLC)

PD-1 and CTLA-4 inhibitors

Arm I: nivolumab with stereotactic radiosurgery

Arm II: nivolumab with whole brain radiation therapy

Arm III: nivolumab and ipilimumab with stereotactic radiosurgeryArm IV: nivolumab and ipilimumab with whole brain radiation therapy

M.D. Anderson Cancer Center

NCT01970527

Phase 2

Melanoma

CTLA-4 inhibitors

Ipilimumab with SBRT

University of Washington

NCT02609503

Phase 2

Head and neck cancer

PD-1 inhibitors

Pembrolizumab with radiation therapy

UNC Lineberger Comprehensive Cancer Center

NCT02730130

Phase 2

Metastatic breast cancer

PD-1 inhibitors

Pembrolizumab with radiation therapy

Memorial Sloan Kettering Cancer Center

NCT02992912

Phase 2

Metastatic tumors

PD-L1 inhibitors

Atezolizumab with SBRT (45 Gy in 3 fractions)

Gustave Roussy, Cancer Campus, Grand Paris

NCT03122509

Phase 2

Metastatic colorectal cancer

PD-L1 and CTLA-4 inhibitors

Tremelimumab and durvalumab with radiation therapy

Memorial Sloan Kettering Cancer Center

NCT02888743

Phase 2

Colorectal cancer and NSCLC

PD-L1 and CTLA-4 inhibitors

Arm I: tremelimumab and durvalumab

Arm II: tremelimumab and durvalumab with high-dose radiation therapy

Arm III: tremelimumab and durvalumab with low-dose radiation therapy

National Cancer Institute (NCI)

NCT02701400

Phase 2

Recurrent SCLC

PD-L1 and CTLA-4 inhibitors

Arm I: tremelimumab and durvalumab

Arm II: tremelimumab and durvalumab with SBRT

Emory University

NCT02617589

Phase 3

Brain Cancer

PD-1 inhibitors

Arm I: nivolumab with radiation therapy

Arm II: temozolomide with radiation therapy

Bristol-Myers Squibb

NCT02768558

Phase 3

NSCLC

PD-1 inhibitors

Cisplatin and etoposide plus radiation followed by nivolumab

RTOG Foundation, Inc.

  1. SCLC small cell lung cancer, NSCLC non-small cell lung cancer, TNBC triple-negative breast cancer, EC esophageal cancer, SBRT stereotactic body radiation therapy